290650 — L&C Bio Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩445bn
- KR₩477bn
- KR₩69bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 28,913 | 27,344 | 19,620 | 12,316 | 59,193 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10,137 | 9,306 | 13,242 | 13,553 | 19,894 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 46,090 | 45,501 | 47,632 | 64,284 | 130,357 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7,287 | 9,483 | 17,895 | 53,138 | 74,655 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 66,226 | 80,576 | 107,401 | 199,725 | 262,230 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,401 | 3,675 | 5,635 | 18,738 | 101,838 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 8,043 | 22,769 | 22,380 | 101,773 | 115,285 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 58,183 | 57,806 | 85,021 | 97,952 | 146,945 |
Total Liabilities & Shareholders' Equity | 66,226 | 80,576 | 107,401 | 199,725 | 262,230 |
Total Common Shares Outstanding |